Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & EquivalentsCurrent AssetsCurrent Deferred RevenueGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLoans - Loss AllowanceNon-Current AssetsOperating LeasesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

RedHill Biopharma (RDHL) Non-Current Deffered Revenue: 2018-2023

Historic Non-Current Deffered Revenue for RedHill Biopharma (RDHL) over the last 6 years, with Dec 2023 value amounting to $540,000.

  • RedHill Biopharma's Non-Current Deffered Revenue fell 28.00% to $540,000 in Q4 2023 from the same period last year, while for Dec 2023 it was $540,000, marking a year-over-year decrease of 28.00%. This contributed to the annual value of $540,000 for FY2023, which is 28.00% down from last year.
  • RedHill Biopharma's Non-Current Deffered Revenue amounted to $540,000 in FY2023, which was down 28.00% from $750,000 recorded in FY2022.
  • RedHill Biopharma's Non-Current Deffered Revenue's 5-year high stood at $750,000 during FY2020, with a 5-year trough of $500,000 in FY2019.
  • In the last 3 years, RedHill Biopharma's Non-Current Deffered Revenue had a median value of $750,000 in 2022 and averaged $680,000.
  • Its Non-Current Deffered Revenue has fluctuated over the past 5 years, first spiked by 50.00% in 2020, then declined by 28.00% in 2023.
  • RedHill Biopharma's Non-Current Deffered Revenue (Yearly) stood at $500,000 in 2019, then skyrocketed by 50.00% to $750,000 in 2020, then remained steady at $750,000 in 2021, then remained steady at $750,000 in 2022, then decreased by 28.00% to $540,000 in 2023.